loading page

Fanconi Anemia: Hematopoietic Stem Cell Transplant or Gene Therapy?
  • +1
  • Parisa Naji,
  • Maryam Behfar,
  • Arefeh Jafarian,
  • Amir Ali Hamidieh
Parisa Naji
Tehran University of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Maryam Behfar
Tehran University of Medical Sciences
Author Profile
Arefeh Jafarian
Tehran University of Medical Sciences
Author Profile
Amir Ali Hamidieh
Pediatric Cell Therapy Research Center, Tehran University of Medical Sciences
Author Profile

Abstract

FA is a rare, multi-organ cancer-prone IBMFS associated with hematological malignancies and STs. The androgen therapy, hematopoietic growth factors, HSCT, and GT, still in the clinical trial, are various treatments for this disease. Here, we aimed to compare the advantages and disadvantages of HSCT and GT in FA cures. We perform an advanced electronic search of “FA” AND (genetics OR treatment OR HSCT OR GT OR Mosaicism), and “Allo-HSCT” AND (conditioning regimen OR complications OR GvHD OR infection OR cost) MeSH terms in non-citation and citation databases. Besides, the gray literature was searched too. This article will provide a summary of the advantages and disadvantages of HSCT and GT of FA disease. Our results show that GT has a good potential in FA treatments in the future. Furthermore, it has higher advantages and fewer disadvantages in comparison with HSCT. Systematic Review Registration: CRD42021247364 ID on PROSPERO database.